China (Mainland) 
treatment arthritis piroxicam (cas no. 36322-90-4)
piroxicam
cas no. 36322-90-4
einecs. 252-974-3
molecular formula. c15h13n3o4s
molecular weight. 331.3464
standard: bp usp ep
appearance: a white or slightly yellow crystalline powder
assay 98.3%
|
tests carried out |
limits |
observations |
|
description |
a white or slightly yellow crystalline powder |
lightly yellow crystalline powder |
|
identification |
a.b.c.positive reaction |
meets the requirements |
|
water |
≤0.5% |
0.02% |
|
resioue on ignition |
≤0.3% |
0.19% |
|
heavy metals |
≤0.005% |
<0.005% |
|
organic wolatice impurities |
conforms to u.s.p.30 |
meets the requirements |
|
solubility |
very slightly soluble in water,in diluite acids and in most organics solvents slightly soluble in alcohol and aqueous alkaline solutions |
meets the requirements |
|
assay |
contain piroxicam not less than 97.0 dereent and not more than 103.0 dereent of c15h13n3o4s |
98.3% |
|
bulk density |
0.4 to 0.8g/ml |
complies |
|
granular size |
100%below 25μ |
complies |
|
conclusion |
it complies with u.s.p.30 |
|
piroxicam appication
piroxicam is a non-steroidal anti-inflammatory drug (nsaid) of the oxicam class used to relieve the symptoms of painful, inflammatory conditions like arthritis. piroxicam works by preventing the production of a certain type of body chemical called prostaglandins which are involved in the mediation of pain, stiffness, tenderness and swelling. the medicine is available as capsules, tablets and (not in all countries) as a prescription-free gel 0.5%. it is also available in a betadex formulation, which allows a more rapid absorption of piroxicam from the digestive tract.
it was originally brought to market by pfizer under the tradename feldene in 1980, became generic in 1992, and is marketed worldwide under many brandnames.
it used in the treatment of rheumatoid and osteoarthritis, primary dysmenorrhoea, postoperative pain; and act as an analgesic, especially where there is an inflammatory component. the european medicines agency issued a review of its use in 2007 and recommended that its use be limited to the treatment of chronic inflammatory conditions, as it only in these circumstances that its risk-benefit ratio proves to be favourable.
piroxicam storage:
should be store in cool and dry place.